DermTech (DermTech) Interest Expense : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is DermTech Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. DermTech's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. DermTech's Operating Income for the three months ended in Mar. 2024 was $ -20.51 Mil. DermTech's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. GuruFocus does not calculate DermTech's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

DermTech Interest Expense Historical Data

The historical data trend for DermTech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DermTech Interest Expense Chart

DermTech Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

DermTech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

DermTech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

DermTech (NAS:DMTK) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

DermTech's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-20.51 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $50.46 Mil.

DermTech's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GuruFocus does not calculate DermTech's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

DermTech (DermTech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » DermTech Inc (NAS:DMTK) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

11099 N. Torrey Pines Road, Suite 100, La Jolla, CA, USA, 92037

Website

https://www.dermtech.com

DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.

Executives

Kevin M Sun	officer: Chief Financial Officer	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Claudia Ibarra	officer: Chief Operating Officer	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Ramin Akhavan	officer: General Counsel	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Mark Bryan Aguillard	officer: Chief Commercial Officer	19800 CORDILL LANE, SPICEWOOD TX 78669
Todd Michael Wood	officer: Chief Commercial Officer	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Bret Christensen	director, officer: Chief Executive Officer	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
John Dobak	director, officer: Chief Executive Officer	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Kirk Malloy	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Mark Christopher Capone	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Herm Rosenman	director	OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
Nathalie Gerschtein Keraudy	director	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Monica Tellado	director	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Enrico Picozza	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew L. Posard	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037